180 related articles for article (PubMed ID: 33632085)
21. Diagnostic Value of Serum hsa-mir-92a in Patients with Cervical Cancer.
Kong Q; Tang Z; Xiang F; Jiang J; Yue H; Wu R; Kang X
Clin Lab; 2017 Feb; 63(2):335-340. PubMed ID: 28182350
[TBL] [Abstract][Full Text] [Related]
22. The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer.
Aghbash PS; Hemmat N; Baradaran B; Mokhtarzadeh A; Poortahmasebi V; Oskuee MA; Baghi HB
Oncol Res; 2022; 30(3):99-116. PubMed ID: 37305016
[TBL] [Abstract][Full Text] [Related]
23. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.
Nagarajan P; El-Hadad C; Gruschkus SK; Ning J; Hudgens CW; Sagiv O; Gross N; Tetzlaff MT; Esmaeli B
Invest Ophthalmol Vis Sci; 2019 May; 60(6):2388-2398. PubMed ID: 31141610
[TBL] [Abstract][Full Text] [Related]
24. Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer.
Aftab M; Poojary SS; Seshan V; Kumar S; Agarwal P; Tandon S; Zutshi V; Das BC
Sci Rep; 2021 May; 11(1):10323. PubMed ID: 33990639
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
[TBL] [Abstract][Full Text] [Related]
26. Difference in vaginal microecology, local immunity and HPV infection among childbearing-age women with different degrees of cervical lesions in Inner Mongolia.
Zheng JJ; Song JH; Yu CX; Wang F; Wang PC; Meng JW
BMC Womens Health; 2019 Aug; 19(1):109. PubMed ID: 31405377
[TBL] [Abstract][Full Text] [Related]
27. Liquid biopsy of HPV DNA in cervical cancer.
Cheung TH; Yim SF; Yu MY; Worley MJ; Fiascone SJ; Chiu RWK; Lo KWK; Siu NSS; Wong MCS; Yeung ACM; Wong RRY; Chen ZG; Elias KM; Chung TKH; Berkowitz RS; Wong YF; Chan PKS
J Clin Virol; 2019 May; 114():32-36. PubMed ID: 30913520
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
29. Correlation between Vaginal Microecological Status and Prognosis of CIN Patients with High-Risk HPV Infection.
Zhang H; Jin S; Ji A; Zhang C; Shi S
Biomed Res Int; 2022; 2022():3620232. PubMed ID: 35463993
[TBL] [Abstract][Full Text] [Related]
30. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials.
Hong AM; Vilain RE; Romanes S; Yang J; Smith E; Jones D; Scolyer RA; Lee CS; Zhang M; Rose B
Oncotarget; 2016 Nov; 7(47):77010-77020. PubMed ID: 27776338
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women.
Tian Q; Li Y; Wang F; Li Y; Xu J; Shen Y; Ye F; Wang X; Cheng X; Chen Y; Wan X; Lu W; Xie X
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25190727
[TBL] [Abstract][Full Text] [Related]
33. A Novel Circulating MiRNA-Based Signature for the Diagnosis and Prognosis Prediction of Early-Stage Cervical Cancer.
Qiu H; Liang D; Liu L; Xiang Q; Yi Z; Ji Y
Technol Cancer Res Treat; 2020; 19():1533033820970667. PubMed ID: 33327867
[TBL] [Abstract][Full Text] [Related]
34. miR-21 and miR29-a: Potential Molecular Biomarkers for HPV Genotypes and Cervical Cancer Detection.
Zamani S; Hosseini SM; Sohrabi A
Microrna; 2020; 9(4):271-275. PubMed ID: 31733640
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
Chen YL; Wang GX; Lin BA; Huang JS
Cell Biol Int; 2020 May; 44(5):1224-1236. PubMed ID: 32068322
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-18a targeting of the STK4/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer.
Morgan EL; Patterson MR; Ryder EL; Lee SY; Wasson CW; Harper KL; Li Y; Griffin S; Blair GE; Whitehouse A; Macdonald A
PLoS Pathog; 2020 Jun; 16(6):e1008624. PubMed ID: 32555725
[TBL] [Abstract][Full Text] [Related]
37. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
Front Immunol; 2019; 10():1644. PubMed ID: 31379843
[No Abstract] [Full Text] [Related]
38. Tumor-associated CD204
Kawachi A; Yoshida H; Kitano S; Ino Y; Kato T; Hiraoka N
Cancer Sci; 2018 Mar; 109(3):863-870. PubMed ID: 29274107
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma.
Jeong JY; Park TI; Ahn D
Anticancer Res; 2020 Jul; 40(7):4001-4010. PubMed ID: 32620644
[TBL] [Abstract][Full Text] [Related]
40. HPV16
Pulati N; Zhang Z; Gulimilamu A; Qi X; Yang J
J Gene Med; 2019 Nov; 21(11):e3126. PubMed ID: 31498525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
